Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
25 Japan Drug Makers See 50% Growth in Operating Profit on FX, Unprofitability Re-Pricing
The combined operating profit of 25 Japanese pharma companies surged nearly 50% over the year in the first half of FY2024 as global players enjoyed a currency tailwind while domestic-oriented firms got a boost from price hikes on unprofitable drugs,…
To read the full story
Related Article
- Net Profit at 24 Japan Drug Makers Tops 2 Trillion Yen, Led by Astellas and Sumitomo
May 25, 2026
- 60% of Japan Drug Makers See Lower Operating Profit in H1 FY2025, R&D Costs Weigh on Mid-Sized Firms
November 21, 2025
- 25 Japan Drug Makers’ Total Operating Profit Tops 2 Trillion Yen for 1st Time: Tally
May 20, 2025
- Where Do Japan Drug Makers Stand? A Comparison with Other Industries and Mega Pharma Peers
December 24, 2024
BUSINESS
- Kyorin Starts Pivotal Study of Chronic Cough DTx in Japan
June 12, 2026
- Lotte Biopharma CVC Invests in Swiss ADC Startup
June 12, 2026
- Ono Seeks Velexbru Nod for CNS Involvement of Malignant Lymphoma
June 12, 2026
- Ono Files Opdivo for Anaplastic Thyroid Cancer
June 12, 2026
- Lilly Warns Against Off-Label Use of Mounjaro
June 11, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…